Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Labetalol is a competitive antagonist at both beta-adrenoceptors (beta1 and beta2) and alpha1-adrenoceptors, leading to decreased cardiac output, peripheral vascular resistance, and reduced blood pressure.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Hypertension (FDA-approved),Hypertensive emergency (off-label),Pregnancy-induced hypertension (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous: Initially 20 mg (0.25 mg/kg for 70 kg) over 2 minutes, then 40-80 mg every 10 minutes until desired response or total 300 mg; or continuous infusion at 0.5-2 mg/min titrated to blood pressure. Switch to oral when stable.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is 6-8 hours; may be prolonged in elderly, hepatic impairment, or renal impairment (up to 16 hours).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Extensively metabolized in the liver via glucuronidation (direct conjugation) and also via CYP2D6 (minor pathway).
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily renal (90-95% as unchanged drug and glucuronide conjugates) and a small amount in feces (<5%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Approximately 50% bound to albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Vd is 0.5-1.2 L/kg; distributes extensively into tissues, including crossing the placenta and entering breast milk.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: 25-40% due to extensive first-pass metabolism; Intravenous: 100%.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific dose adjustment required for GFR >15 m L/min; for GFR <15 m L/min or dialysis, use with caution and consider reducing dose. Monitor for hypotension and bradycardia.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh A: No adjustment required. Child-Pugh B: Reduce dose by 50% and titrate slowly. Child-Pugh C: Contraindicated due to extensive hepatic metabolism.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous: 0.2-0.5 mg/kg/dose every 10 minutes as needed, up to 1 mg/kg total. Continuous infusion: 0.25-3 mg/kg/hour. Maximum single dose: 1 mg/kg.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start with low end of dosing range (e.g., 10-20 mg IV initial), titrate cautiously due to increased sensitivity and risk of hypotension, bradycardia, and bronchospasm.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA boxed warning.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause bronchospasm in patients with asthma/COPD; may mask symptoms of hypoglycemia or thyrotoxicosis; may cause severe bradycardia; discontinue if signs of hepatic injury occur; use caution in patients with heart failure or diabetes.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to labetalol; bronchial asthma; overt cardiac failure; cardiogenic shock; severe bradycardia; heart block greater than first degree; severe hypotension.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid alcohol, which can enhance hypotensive and sedative effects. No significant food interactions are documented, but a balanced diet is recommended. Maintain adequate fluid intake to prevent dehydration-induced hypotension.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
First trimester: Limited human data; animal studies show no major teratogenic effects at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, hypotension, hypoglycemia, and intrauterine growth restriction due to beta-blockade. Risk of preterm delivery and respiratory depression at birth.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Excreted into breast milk in small amounts; average milk-to-plasma ratio (M/P) 0.15-0.80. Considered compatible with breastfeeding by American Academy of Pediatrics, but monitor infant for bradycardia and hypotension.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy may increase clearance and volume of distribution, potentially requiring dose escalation. However, dose adjustments should be guided by clinical response and tolerability. Start at lowest effective dose and titrate carefully. No standard dose adjustment recommended; individualize based on maternal blood pressure and fetal well-being.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Labetalol combines alpha-1 and non-selective beta-blockade, causing less reflex tachycardia than pure beta-blockers. It is a pregnancy category C drug but is commonly used for hypertensive emergencies in pregnancy (e.g., preeclampsia). Monitor for orthostatic hypotension, especially during IV administration. Avoid in patients with bronchial asthma, heart block, or severe bradycardia. May mask symptoms of hypoglycemia and thyrotoxicosis.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Do not stop taking this medication suddenly; abrupt withdrawal may worsen chest pain or cause a heart attack.,This drug may cause dizziness or lightheadedness, especially when standing up quickly; rise slowly from sitting or lying down.,Avoid alcohol, as it may increase dizziness and drowsiness.,Inform all healthcare providers that you are taking labetalol, especially before surgery or dental procedures.,If you have diabetes, monitor blood sugar closely, as labetalol can mask signs of low blood sugar.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Labetalol, a non-selective beta-blocker with additional alpha-1 blocking activity, may augment the vasodilatory effects of epoprostenol, a prostacyclin analog used for pulmonary arterial hypertension. This additive hypotensive effect can lead to symptomatic hypotension, dizziness, syncope, or compromised organ perfusion, particularly during dose titration of either agent. Close hemodynamic monitoring is warranted to prevent adverse outcomes."
"Phenelzine, a nonselective monoamine oxidase inhibitor (MAOI), increases norepinephrine and epinephrine stores in sympathetic nerve terminals. Labetalol, a nonselective beta-blocker with alpha-1 blocking activity, normally can be taken up by adrenergic neurons; however, in the presence of MAOIs, labetalol may cause a hypertensive response due to unopposed alpha-adrenergic activity from accumulated catecholamines. This can lead to an exaggerated increase in blood pressure instead of the intended hypotensive effect, posing a risk of hypertensive crisis."
"Labetalol, a non-selective beta-blocker with additional alpha-1 blocking activity, may antagonize the antihypertensive effects of azelastine, an H1-antihistamine that also has mild vasodilatory properties. Beta-blockers like labetalol can blunt compensatory sympathetic responses and reduce cardiac output, potentially counteracting azelastine's ability to lower blood pressure. This interaction may lead to diminished antihypertensive efficacy and require dose adjustments or alternative therapy."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is a Electrolyte that works by Labetalol is a competitive antagonist at both beta-adrenoceptors (beta1 and beta2) and alpha1-adrenoceptors, leading to decreased cardiac output, peripheral vascular resistance, and reduced blood pressure.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is: Intravenous: Initially 20 mg (0.25 mg/kg for 70 kg) over 2 minutes, then 40-80 mg every 10 minutes until desired response or total 300 mg; or continuous infusion at 0.5-2 mg/min titrated to blood pressure. Switch to oral when stable.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE is classified as Category A/B. First trimester: Limited human data; animal studies show no major teratogenic effects at clinically relevant doses. Second and third trimesters: Associated with fetal bradycardia, . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.